Evaluating Next Steps for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

Robert L. Coleman, MD, discusses the next steps for tisotumab vedotin following the presentation of findings from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study in patients with previously treated recurrent or metastatic cervical cancer.

Robert L. Coleman, MD, chief scientific officer, The US Oncology Network, discusses the next steps for tisotumab vedotin following the presentation of findings from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study in patients with previously treated recurrent or metastatic cervical cancer.

This study met its primary end point of objective response rate, which was clinically and significantly improved. Based on this, Coleman says the next step would be to pursue regulatory action, such as an accelerated approval from the FDA. Another next step would be to develop a phase 3 study to evaluate this agent against chemotherapy.

Coleman says an important next step, considering the positive single-agent activity observed in the study, would be to see what tisotumab vedotin could be combined with to improve outcomes further. A number of studies are now ongoing, evaluating potential combinations, such as with immunotherapy or anti-angiogenesis therapy, as well as in different lines and different schedules. This will help to expand our knowledge of the best dosing frequency.